Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
NCT01467661Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2010
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anagrelide in essential thrombocythemia (ET), sponsored by Takeda. Started Oct 2010; status: completed.
02
Drugs
anagrelide
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT01467661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01467661.